Text and Data Mining valid from 2019-09-09
Received: 14 May 2019
Accepted: 27 August 2019
First Online: 9 September 2019
Ethics approval and consent to participate
: The study was conducted according to the Declaration of Helsinki and the national research regulations. The study received approval by the Institutional Review Board of Corporación Científica Pediátrica in Cali, Colombia (reference number CEI-060-2016). All subjects who agreed to participate in the research provided written informed consent to participate.
: No individual patient data is presented, therefore consent to publish was not requested.
: EMB reports research grants from ViiV Healthcare/GSK, financial support for REVIVA foundation and VIHCOL Group (Grupo Colombiano de VIH) from GSK, MSD and Stendhal, and personal fees for presentations and advisory board meetings from GSK, MSD and Stendhal and presentations from Janssen Pharmaceuticals. JMO reports grants from ViiV Healthcare/GlaxoSmithKline, and personal fees from Merck Sharp & Dohme Colombia. JFO reports personal fees from Merck Sharp and Dohme Colombia. JA reports grants from ViiV Healthcare/GlaxoSmithKline and grants and personal fees from Merck Sharp & Dohme Colombia SAS. WL reports grants from ViiV Healthcare/GlaxoSmithKline, personal fees from Janssen Cilag SA, and Merck Sharp & Dohme Colombia; LR reports grants from ViiV Healthcare/GSK and Merck Sharp & Dohme Colombia. LMS declares no conflicts of interest.